Retatrutide vs Tirzepatide
A comprehensive, data-driven comparison of Retatrutide (LY3437943) and Tirzepatide (Mounjaro). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Retatrutide LY3437943 | Tirzepatide Mounjaro, Zepbound |
|---|---|---|
| FDA Status | Phase 3 | FDA Approved |
| Category | Weight Loss | Weight Loss |
| Primary Use | Obesity and weight management | Type 2 diabetes and chronic weight management |
| Weight Loss % | 28.7% | 22.5% |
| Monthly Cost | $1,200 - $1,500/mo | $1,100 - $1,500/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 12mg weekly (dose escalated from 2mg) | 15mg weekly (max dose) |
| Frequency | Weekly | Weekly |
| Mechanism | Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion, reduce appetite, and increase energy expenditure | Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric emptying, and decreases appetite |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | High |
| Clinical Trial Phase | Phase 3 | Approved |
Key Differences
- 1Tirzepatide is FDA-approved, while Retatrutide is currently phase 3.
- 2Retatrutide showed 28.7% average weight loss in trials compared to 22.5% for Tirzepatide.
- 3Tirzepatide is generally more affordable ($1,100 - $1,500/mo) compared to Retatrutide ($1,200 - $1,500/mo).
Which Is Better For...
Tirzepatide
Those seeking an FDA-approved treatment with established safety data
Retatrutide
Maximum weight loss efficacy based on clinical trial data
Tirzepatide
More budget-friendly option with lower monthly costs
Retatrutide
Fewer commonly reported side effects
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Retatrutide | $1,200 - $1,500/mo | Phase 3 | Eli Lilly |
| Tirzepatide | $1,100 - $1,500/mo | FDA Approved | Eli Lilly |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Retatrutide works via Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion,. Tirzepatide works via Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric. They differ in FDA approval status, efficacy data, and cost.
In clinical trials, Retatrutide showed greater average weight loss (28.7%) compared to Tirzepatide (22.5%). Individual results may vary.
Retatrutide typically costs $1,200 - $1,500/mo, while Tirzepatide costs $1,100 - $1,500/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Retatrutide is not FDA-approved (Phase 3). Tirzepatide is FDA-approved. FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Retatrutide include Nausea, Diarrhea, Vomiting. Common side effects of Tirzepatide include Nausea, Diarrhea, Decreased appetite. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Retatrutide is a novel triple-receptor agonist developed by Eli Lilly currently in Phase 3 clinical trials. It has demonstrated unprecedented weight loss results, with patients losing an average of 28...
View Full Retatrutide GuideTirzepatide is a dual-action peptide approved by the FDA as Mounjaro for type 2 diabetes and Zepbound for weight management. It is the first medication to target both GIP and GLP-1 receptors simultane...
View Full Tirzepatide GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Retatrutide and Tirzepatide should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.